Metraipolis › archive › dc_7fc727779852

Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial — Europe PMC PMID:41904616

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41904616
DOI
10.1681/asn.0000001076
License (as archived)
solo-consultazione
Archived
2026-11-03T17:37:17.848Z
SHA-256 of the archived text
23ecd5fe31a77bf067a9ca4006befda8aeda5472e533e65fc514967be0c62502
Stable URL of this page
https://metraipolis.com/documento/dc_7fc727779852

How to cite

Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial — Europe PMC PMID:41904616 — Europe PMC (en), https://europepmc.org/article/MED/41904616 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7fc727779852 (Metraipolis archive dc_7fc727779852, sha256 23ecd5fe31a77bf067a9ca4006befda8aeda5472e533e65fc514967be0c62502)
BibTeX
@misc{dc7fc727779852,
  title = {Efficacy and Safety of Atrasentan in Patients with IgA Nephropathy Receiving Sodium-Glucose Cotransporter 2 Inhibitors: Placebo-Controlled, Crossover Trial — Europe PMC PMID:41904616},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41904616},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7fc727779852; sha256 23ecd5fe31a77bf067a9ca4006befda8aeda5472e533e65fc514967be0c62502},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41904616. Agents can read the archived copy with the MCP tool read_document.